Examples of using Abilify in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Take Abilify once a daily with or without food.
Aripiprazole is an atypical anti-psychotic sold under the brand name Abilify®.
Abilify Maintena comes as a pre-filled syringe.
The incidence of weight loss of≥ 7% frombaseline to last visit was 6.4% for Abilify Maintena and 6.7% for placebo.
Abilify® is a registered trademark of Otsuka Pharmaceutical Co., Ltd.
The company carried out‘bioequivalence' studies to show that Aripiprazole Sandoz is bioequivalent to the reference medicine, Abilify.
Abilify Maintena comes as a white to off-white powder in a clear glass vial.
For example, Effexor(venlafaxine)by Pfizer can bring on mania in a bipolar person and Abilify(aripiprazole) by Bristol-Myers-Squibb can give you suicidal thoughts.
Abilify Maintena comes as a powder which your doctor or nurse will make into a suspension.
These medicines may increase the risk of side effects;if you get any unusual symptom taking any of these medicines together with Abilify Maintena, you should see your doctor.
Abilify(Aripirazole) is an antipsychotic medication which is primarily prescribed to treat bipolar disorder, schizophrenia, and depression.
Aripiprazole is an atypical antipsychotic and the active ingredient in Abilify®, a leading medication in the US used for the treatment of a number of psychiatric disorders including bipolar I disorder, schizophrenia.
Abilify Maintena comes in a pre-filled syringe containing a white to off-white powder in the front chamber and a clear solvent in the rear chamber.
Your doctor or nurse will make it into a suspension that will begiven as an injection using the vial of solvent for Abilify Maintena that comes as a clear solution in a clear glass vial.
The dose of Abilify should be adjusted in patients who are taking other medicines that are broken down in the same way as Abilify.
Based on this plan, safety information has been included in the summary of product characteristics andthe package leaflet for Abilify Maintena, including the appropriate precautions to be followed by healthcare professionals and patients.
Abilify is used to treat moderate to severe manic episodes and to prevent manic episodes in patients who have responded to the medicine in the past.
The estimated proportion of patients experiencingimpending relapse by end of Week 26 for Abilify Maintena was 7.12%, which was statistically significantly lower than in aripiprazole Long-Acting Injectable 50 mg/25 mg 21.80%; p 0.0006.
Receiving Abilify Maintena with some medicines may mean the doctor will need to change your dose of Abilify Maintena or the other medicines.
In one main study involving adults whose disease had already been stabilised on treatment with aripiprazole taken by mouth, 22 out of the 265 patients(8.3%)treated with Abilify Maintena had symptoms coming back within 26 weeks, compared with 21 out of 266(7.9%) patients treated with aripiprazole taken by mouth.
The most common side effects with Abilify Maintena(which may affect 5 or more people in 100) are increased weight, akathisia(a constant urge to move), insomnia(difficulty sleeping) and injection site pain.
In both studies of the solution for injection, patients receiving Abilify at doses of 5.25, 9.75 or 15 mg had a significantly greater reduction in symptoms of agitation than those receiving placebo.
Abilify is prescribed for the treatment of such conditions as major depressive disorder, schizophrenia, manic and mixed episodes associated with bipolar disorder in adults and children and adolescents and also of irritability associated with autistic disorder in children.
In the placebo group39.6% of the patients had progressed to impending relapse, whilst in the Abilify Maintena group impending relapse occurred in 10% of the patients; thus patients in the placebo group had a 5.03-fold greater risk of experiencing impending relapse.
Abilify is an add-on medication used for the treatment of major depressive disorder, schizophrenia, manic and mixed episodes associated with bipolar disorder in adults and children and adolescents and also of irritability associated with autistic disorder in pediatric patients.
Concomitant use of CYP3A4 inducers with Abilify Maintena should be avoided for more than 14 days because the blood levels of aripiprazole are decreased and may be below the effective levels see section 4.5.
The effectiveness of Abilify solution for injection was compared with that of lorazepam(another antipsychotic medicine) and of placebo over a period of two hours in one study involving 301 patients with bipolar disorder who were experiencing symptoms of agitation.
The Committee for Medicinal Products for Human Use(CHMP) decided that Abilify' s benefits are greater than its risks for the treatment of schizophrenia and of moderate to severe manic episodes in bipolar I disorder, and for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.
Another study compared Abilify with haloperidol over 12 weeks in 347 patients, and a further study compared the effectiveness of Abilify and placebo in preventing recurrence in 160 patients whose manic symptoms had already been stabilised using Abilify.
The most common side effects when taking Abilify by mouth(seen in between 1 and 10 patients in 100) are extrapyramidal disorder(uncontrolled twitching or jerking), akathisia(constant urge to move), tremor(shaking), somnolence(sleepiness), sedation(drowsiness), headache, blurred vision, dyspepsia(heartburn), vomiting, nausea(feeling sick), constipation, salivary hypersecretion(increased production of saliva), fatigue(tiredness), restlessness, insomnia(difficulty sleeping) and anxiety.